458 related articles for article (PubMed ID: 25884545)
21. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
Chahal R; Darshane A; Browning AJ; Sundaram SK
Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
[TBL] [Abstract][Full Text] [Related]
24. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
[TBL] [Abstract][Full Text] [Related]
25. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
26. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
27. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
28. [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
Gonzalo Rodríguez V; Sanz Justo L; de Miguel Santamaría I; Martínez de Iturrate J; Fernández del Busto E
Arch Esp Urol; 2008 Apr; 61(3):377-84. PubMed ID: 18581675
[TBL] [Abstract][Full Text] [Related]
29. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
30. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
31. Detection of bladder cancer using a point-of-care proteomic assay.
Grossman HB; Messing E; Soloway M; Tomera K; Katz G; Berger Y; Shen Y
JAMA; 2005 Feb; 293(7):810-6. PubMed ID: 15713770
[TBL] [Abstract][Full Text] [Related]
32. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
34. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
35. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
36. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
37. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
[TBL] [Abstract][Full Text] [Related]
38. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of urine NMP22 point-of-care test for the screening of bladder cancer].
Ihm CH; Kim JM; Sohn YH
Korean J Lab Med; 2007 Apr; 27(2):106-10. PubMed ID: 18094560
[TBL] [Abstract][Full Text] [Related]
40. Urine markers for bladder cancer surveillance: a systematic review.
van Rhijn BW; van der Poel HG; van der Kwast TH
Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
